Outcomes of Oral Vinorelbine in Progressive Desmoid Fibromatosis-Response.

Olivier Mir,Charles Honoré,Ali N Chamseddine,Matthieu Faron,Leila Haddag-Miliani,Arnaud Bayle,Axel Le Cesne

CLINICAL CANCER RESEARCH（2021）

Cited 0|Views1

No score

Abstract

We thank Zheng and colleagues for their interest in our article long-term outcomes of oral vinorelbine in advanced, progressive desmoid fibromatosis and influence of CTNNB1 mutational status ([1][1]). Their letter addresses relevant points concerning the use of a fixed dose of vinorelbine, and the

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined